The intrinsic ATPase activity of protein kinase C is catalyzed at the active site of the enzyme.
We recently reported that autophosphorylated protein kinase C (PKC) has an intrinsic Ca(2+)- and phospholipid-dependent ATPase activity and that the ATPase and histone kinase activities of PKC have similar metal-ion cofactor requirements and Km,app(ATP) values. We hypothesized that the intrinsic ATPase activity of PKC may represent the bond-breaking step of its protein kinase activity. The rate of the ATPase reaction is several times slower than the histone kinase reaction rate. At subsaturating concentrations, various peptide and protein substrates stimulate the ATPase reaction by as much as 1.5-fold. In contrast, non-phosphorylatable substrate analogs are not stimulatory. These observations support a mechanism of PKC catalysis in which the productive binding of phosphoacceptor substrates enhances the rate of phosphodonor substrate (ATP) hydrolysis at the active site of PKC. However, this mechanism contains an assumption that the ATPase activity of PKC is catalyzed at the active site. In fact, sequence analysis indicates that PKC contains a potential second nucleotide binding site outside of its active site. In this report, we provide a detailed analysis of the relationship between the active site of PKC and the intrinsic ATPase activity of the enzyme. We show that the regulatory and catalytic properties of the ATPase reactions of three PKC isozymes are similar, despite critical differences among the isozymes in their consensus sequences for the potential non-active-site nucleotide binding site in their catalytic domains. We also show that the ATPase and histone kinase reactions of each isozyme have similar Km,app(ATP) values.(ABSTRACT TRUNCATED AT 250 WORDS)
Ward
N E
NE
Department of Cell Biology, University of Texas M. D. Anderson Cancer Center, Houston 77030.
O'Brian
C A
CA
D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000085:Acetates / Q000494:pharmacology; D019342:Acetic Acid; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000255:Adenosine Triphosphate / Q000378:metabolism; D000818:Animals; D000911:Antibodies, Monoclonal; D001665:Binding Sites; D001667:Binding, Competitive; D001921:Brain / Q000201:enzymology; D002118:Calcium / Q000494:pharmacology; D002384:Catalysis; D007527:Isoenzymes / Q000378:metabolism*; D007546:Isoquinolines / Q000494:pharmacology; D007700:Kinetics; D010718:Phosphatidylserines / Q000494:pharmacology; D010766:Phosphorylation; D010879:Piperazines / Q000494:pharmacology; D011189:Potassium Chloride / Q000494:pharmacology; D011493:Protein Kinase C / Q000378:metabolism*; D051381:Rats; D012965:Sodium Chloride / Q000494:pharmacology; D013379:Substrate Specificity
D000085:Acetates; D000911:Antibodies, Monoclonal; D007527:Isoenzymes; D007546:Isoquinolines; D010718:Phosphatidylserines; D010879:Piperazines; D012965:Sodium Chloride; D011189:Potassium Chloride; D019307:1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; D000255:Adenosine Triphosphate; D011493:Protein Kinase C; D000251:Adenosine Triphosphatases; D019342:Acetic Acid; D002118:Calcium